{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:42:35Z","timestamp":1783690955947,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10637-019-00873-6","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T14:03:03Z","timestamp":1573308183000},"page":"1145-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer"],"prefix":"10.1007","volume":"38","author":[{"given":"Johanna C.","family":"Bendell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge G.","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Hynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Pitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne L.","family":"Farrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Bell-McGuinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,9]]},"reference":[{"key":"873_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","volume":"108","author":"J Smith","year":"2010","unstructured":"Smith J, Tho LM, Xu N, Gillespie DA (2010) The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108:73\u2013112","journal-title":"Adv Cancer Res"},{"issue":"2","key":"873_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ceb.2009.01.018","volume":"21","author":"HC Reinhardt","year":"2009","unstructured":"Reinhardt HC, Yaffe MB (2009) Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 21(2):245\u2013255","journal-title":"Curr Opin Cell Biol"},{"issue":"9","key":"873_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrm3640","volume":"14","author":"HC Reinhardt","year":"2013","unstructured":"Reinhardt HC, Yaffe MB (2013) Phospho-Ser\/Thr-binding domains: navigating the cell cycle and DNA damage response. Nat Rev Mol Cell Biol 14(9):563\u2013580","journal-title":"Nat Rev Mol Cell Biol"},{"key":"873_CR4","first-page":"70","volume":"6","author":"RG Sylju\u00e5sen","year":"2015","unstructured":"Sylju\u00e5sen RG, Hasvold G, Hauge S, Helland \u00c5 (2015) Targeting lung cancer through inhibition of checkpoint kinases. Front Genet 6:70","journal-title":"Front Genet"},{"issue":"2","key":"873_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ncb1212","volume":"7","author":"CS S\u00f8rensen","year":"2005","unstructured":"S\u00f8rensen CS, Hansen LT, Dziegielewski J, Sylju\u00e5sen RG, Lundin C, Bartek J et al (2005) The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7(2):195\u2013201","journal-title":"Nat Cell Biol"},{"issue":"9","key":"873_CR6","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1128\/MCB.25.9.3553-3562.2005","volume":"25","author":"RG Sylju\u00e5sen","year":"2005","unstructured":"Sylju\u00e5sen RG, S\u00f8rensen CS, Hansen LT, Fugger K, Lundin C, Johansson F et al (2005) Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 25(9):3553\u20133562","journal-title":"Mol Cell Biol"},{"issue":"1","key":"873_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2013.10.005","volume":"142","author":"S McNeely","year":"2014","unstructured":"McNeely S, Beckmann R, Bence Lin AK (2014) CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther 142(1):1\u201310","journal-title":"Pharmacol Ther"},{"issue":"3","key":"873_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bcp.12139","volume":"76","author":"R Thompson","year":"2013","unstructured":"Thompson R, Eastman A (2013) The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. Br J Clin Pharmacol 76(3):358\u2013369","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"873_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1124\/mi.11.2.11","volume":"11","author":"P Dent","year":"2011","unstructured":"Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S (2011) CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv 11(2):133\u2013140","journal-title":"Mol Interv"},{"issue":"15","key":"873_CR10","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1200\/JCO.2015.64.5788","volume":"34","author":"D Hong","year":"2016","unstructured":"Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H et al (2016) Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer. J Clin Oncol 34(15):1764\u20131771","journal-title":"J Clin Oncol"},{"issue":"2","key":"873_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","volume":"11","author":"HC Reinhardt","year":"2007","unstructured":"Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage. Cancer Cell 11(2):175\u2013189","journal-title":"Cancer Cell"},{"issue":"1","key":"873_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cell.2015.05.053","volume":"162","author":"F Dietlein","year":"2015","unstructured":"Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L et al (2015) A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell. 162(1):146\u2013159","journal-title":"Cell."},{"issue":"9","key":"873_CR13","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-14-1037","volume":"14","author":"C King","year":"2015","unstructured":"King C, Diaz HB, McNeely S, Barnard D, Dempsey J, Blosser W et al (2015) LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms. Mol Cancer Ther 14(9):2004\u20132013","journal-title":"Mol Cancer Ther"},{"key":"873_CR14","doi-asserted-by":"crossref","unstructured":"Wu W, Bi C, Bence AK, Um SL, Yan B, Starling JJ et al (2012) Abstract 1776: Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model. Cancer Res 72(8 Suppl):1776","DOI":"10.1158\/1538-7445.AM2012-1776"},{"issue":"14","key":"873_CR15","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1158\/1078-0432.CCR-17-3347","volume":"24","author":"DS Hong","year":"2018","unstructured":"Hong DS, Moore K, Patel M, Grant SC, Burris HA III, William WN Jr et al (2018) Evaluation of prexasertib, a checkpoint kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma. Clin Cancer Res 24(14):3263\u20133272","journal-title":"Clin Cancer Res"},{"issue":"2","key":"873_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1158\/1535-7163.MCT-13-0513","volume":"13","author":"RM Campbell","year":"2014","unstructured":"Campbell RM, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A et al (2014) Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther 13(2):364\u2013374","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"873_CR17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1158\/1078-0432.CCR-15-1718","volume":"22","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL et al (2016) A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer. Clin Cancer Res 22(5):1095\u20131102","journal-title":"Clin Cancer Res"},{"issue":"2","key":"873_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"6","key":"873_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"issue":"13","key":"873_CR20","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/sim.3230","volume":"27","author":"B Neuenschwander","year":"2008","unstructured":"Neuenschwander B, Branson M, Gsponer T (2008) Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 27(13):2420\u20132439","journal-title":"Stat Med"},{"issue":"6","key":"873_CR21","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 3(6):285\u2013290","journal-title":"Arzneimittelforschung."},{"issue":"2","key":"873_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1128\/MMBR.68.2.320-344.2004","volume":"68","author":"PP Roux","year":"2004","unstructured":"Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68(2):320\u2013344","journal-title":"Microbiol Mol Biol Rev"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00873-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00873-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00873-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:42:07Z","timestamp":1678509727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00873-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,9]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["873"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00873-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,9]]},"assertion":[{"value":"9 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Bendell reports the following: grants (payment to institution for conduct of clinical trials for which Dr. Bendell served as PI) from EMD Serono, Koltan, SynDevRex, Forty Seven, Abbvie, Onyx, Takeda, Eisai, CellDex, Cytomx, Nektar, Boston Biomedical, Tarveda, Tyrogenex, Marshall Edwards, Pieris, Pfizer, Mersana, Calithera, Blueprint, Evelo, Merus, Jacobio, Effector, Novocare, Arrys, tracon, Sierra, Unum Therapeutics, Vyriad, Harpoon, Acerta Pharma, Rgenix, Millennium, ImClone, ADC, and Bellicum; grants and consulting services (payment to institution for conduct of clinical trials for which Dr. Bendell served as PI, and payment to institution for consulting services by Dr. Bendell) from Gilead, Genentech\/Roche, Bristol Myers Squibb, Five prime, Eli Lilly, Merck, MedImmune, Celgene, Taiho, Marcogenics, GSK, Novartis, OncMed, LEAP, TG Therapeutics, Astra Zeneca, BI, Bayer, Apexgen, Array, Prelude Oncology, Sanofi, Agios, ARMO, Ispen, Merrimack, Oncogenex, FORMA, Innate, Arch Oncology, and Amgen; consulting services (payment to institution for consulting services by Dr. Bendell) from Phoenix Bio, Cyteir, Molecular Partners, Torque, Tizona, Translational Drug Development, Seattle Genetics, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, and Continuum Clinical.Dr. Bischoff has nothing to disclose.Dr. Hwang has nothing to disclose.Dr. Reinhardt has nothing to disclose.Dr. Zander reports serving on advisory boards from Roche, BMS, MSD, Novartis, Pfizer, and Eli Lilly.Dr. Bell-McGuinn, Dr. Campbell, and Dr. Wang are employees and shareholders of Eli Lilly.Dr. Hynes, Dr. Iversen, Dr. Pitou are employees of Eli Lilly.D. Farrington is an employee and shareholder of Verastem Oncology, and reports personal fees and is a shareholder of Eli Lilly, and is a shareholder of Sesen Bio Inc.Dr. Thomas reports personal fees from AbbVie, grants, personal fees and non-financial support from Bristol-Myers Squibb, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Lilly, personal fees and non-financial support from MSD, personal fees and non-financial support from Novartis, grants and personal fees from Roche, and grants from AstraZeneca, during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was registered at  as NCT02860780. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}